Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | CheckMate 205 study of nivo plus AVD in cHL: 2-year follow-up

Stephen Ansell • 2 Jul 2019
ICML 2019
Hodgkin Lymphoma Lymphoma Antibodies Checkpoint inhibitors Nivolumab
CheckMate 205

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, gives an update on the 2-year follow-up of cohort D of the CheckMate 205 study (NCT02181738), which investigated pembrolizumab for the treatment of classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Stephen Ansell

Lymphovision: an AI model for histology-based lymphoma classification and subtyping
1:45
Lymphovision: an AI model for histology-based lymphoma classification and subtyping
Stephen Ansell • 5 Dec 2025
Advances in Hodgkin lymphoma: novel treatments and innovative methods to measure efficacy
1:25
Advances in Hodgkin lymphoma: novel treatments and innovative methods to measure efficacy
Stephen Ansell • 5 Dec 2025
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more
15:05
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more
Stephen Ansell • 27 Sep 2025
How the Hodgkin lymphoma treatment landscape is evolving & future directions
1:09
How the Hodgkin lymphoma treatment landscape is evolving & future directions
Stephen Ansell • 19 Jun 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Stephen Ansell • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Stephen Ansell • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Stephen Ansell • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Stephen Ansell • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals